Previous close | 16.76 |
Open | 16.95 |
Bid | 17.02 x 100 |
Ask | 17.14 x 200 |
Day's range | 16.58 - 17.20 |
52-week range | 9.40 - 17.20 |
Volume | |
Avg. volume | 161,833 |
Market cap | 691.396M |
Beta (5Y monthly) | 0.74 |
PE ratio (TTM) | 46.14 |
EPS (TTM) | 0.37 |
Earnings date | 08 May 2024 |
Forward dividend & yield | 0.48 (2.81%) |
Ex-dividend date | 05 Mar 2024 |
1y target est | 10.75 |
Phibro (PAHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Top animal health company Zoetis Inc will sell its medicated feed additive portfolio and certain other assets to animal nutrition company Phibro Animal Health in a $350 million deal, the two companies said on Sunday. The agreement would also involve some of Zoetis' water soluble products and six manufacturing sites across the U.S., Italy and China, the firms said in a statement. More than 300 Zoetis employees across manufacturing, distribution and commercial activities would transition to Phibro Animal Health, they said.
PARSIPPANY, N.J. & TEANECK, N.J., April 28, 2024--Zoetis Inc. (NYSE:ZTS) and Phibro Animal Health Corporation (Nasdaq: PAHC) today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024.